SCHEMBL4533347

SCHEMBL4533347

COCCc1nc2cnc3ccc(C=CN4C(=O)c5ccccc5C4=O)cc3c2n1CCCN1CCCC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.42
▸ HDAC8 Q9BY41 2/20 0.42
▸ RCE1 Q9Y256 1/20 0.35
▸ ALOX15 P16050 1/20 0.34
▸ ALDH1A1 P00352 6/20 0.34
▸ KDM4E B2RXH2 4/20 0.34
▸ HSD17B10 Q99714 3/20 0.34
▸ HPGD P15428 2/20 0.34
▸ GLA P06280 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ CASP1 P29466 1/20 0.34
▸ CASP7 P55210 1/20 0.34
▸ TYRO3 Q06418 5/20 0.33
▸ MAPK1 P28482 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MET P08581 2/20 0.33
▸ AXL P30530 2/20 0.33
▸ MERTK Q12866 2/20 0.33
▸ SELP P16109 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4533344 1.00 HDAC1 (0.42) HDAC1HDAC8RCE1ALOX15ALDH1A1
SCHEMBL4520877 0.85 TYRO3 (0.38) HDAC1HDAC8RCE1ALOX15ALDH1A1
SCHEMBL4535702 0.84 HDAC1 (0.46) HDAC1HDAC8RCE1ALDH1A1KDM4E
SCHEMBL4535700 0.84 HDAC1 (0.46) HDAC1HDAC8RCE1ALDH1A1KDM4E
SCHEMBL3872563 0.82 ALDH1A1 (0.39) HDAC1HDAC8RCE1ALDH1A1KDM4E
SCHEMBL3870501 0.79 RCE1 (0.43) HDAC1HDAC8RCE1ALDH1A1KDM4E
SCHEMBL3862390 0.78 ALDH1A1 (0.41) HDAC1HDAC8RCE1ALDH1A1KDM4E
SCHEMBL4535714 0.77 TYRO3 (0.39) HDAC1HDAC8RCE1ALDH1A1KDM4E
SCHEMBL4533687 0.74 TYRO3 (0.38) HDAC1HDAC8ALDH1A1TYRO3MAPK1
SCHEMBL4519398 0.72 TLR7 (0.45) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658666-B2 Substituted imidazoquinolines and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-02-25 — — US disclosed
US-20090099161-A1 Substituted Imidazoquinolines and Imidazonaphthyridines COLEY PHARMACEUTIAL GROUP, INC. (NY) 2009-04-16 — — US disclosed
EP-1845988-A2 SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES 3M Innovative Properties Company (US) 2007-10-24 — — EP disclosed
WO-2006091394-A2 SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099161-A1 Substituted Imidazoquinolines and Imidazonaphthyridines IL2, EIF2AK2, IFNG HDAC1 562/4885HDAC8 270/4885RCE1 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback